Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

BioDrugs

Volumn 25, Issue 4, 2011, Pages 217-226

  Garon, Nathalie ^a   Morel, Sandra ^a   Didierlaurent, Arnaud ^a   Descamps, Dominique ^a   Wettendorff, Martine ^a   Van Mechelen, Marcelle ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvants; AS04A; AS04B; Cervical cancer; Human papillomavirus vaccine; Monophosphoryl lipid A; Vaccines

Indexed keywords

ADJUVANT SYSTEM 04; ALUMINUM HYDROXIDE; ALUMINUM SULFATE; AMORPHOUS ALUMINUM HYDROXYPHOSPHATE SULFATE; AS 04; CANCER VACCINE; CHEMOKINE; CYTOKINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; GROUPS BY AGE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE REACTION; INNATE IMMUNITY; MEMORY CELL; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UTERINE CERVICITIS; UTERINE CERVIX; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; HUMANS; LIPID A; PAPILLOMAVIRUS VACCINES;

EID: 80051518347     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11591760-000000000-00000     Document Type: Review

References (70)

1. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR-4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183: 6186-97
2. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298 (18): 2155-63 (Pubitemid 350106654)
3. Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11 (4 Suppl.): S5-11
4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124 (4): 783-801 (Pubitemid 43261452)
5. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296 (5566): 301-5 (Pubitemid 34303674)
6. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006; 102 (1): 10-5
7. Gupta RK, Rost BE, Relyveld E, et al. Adjuvant properties of aluminium and calcium compounds. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995
8. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25 (19): 3752-62 (Pubitemid 46589757)
9. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5 (7): 505-17 (Pubitemid 46925379)
10. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998; 7 (9): 1475-82 (Pubitemid 28408808)
11. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15 (11): 1209-13 (Pubitemid 27372102)
12. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6 (5): 723-39 (Pubitemid 47607848)
13. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2003; 2 (2): 189-96 (Pubitemid 36559924)
14. Moser C, Amacker M, Kammer AR, et al. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 2007; 6 (5): 711-21 (Pubitemid 47610491)
15. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 2007; 82 (6): 740-4 (Pubitemid 350114825)
16. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24 (33-34): 5937-49
17. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, doubleblind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200 (3): 337-46
18. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370 (9587): 580-9 (Pubitemid 47247854)
19. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372 (9653): 1881-93
20. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 2000; 406 (6797): 793-8
21. Boasso A, Shearer GM, Chougnet C. Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it? J Intern Med 2009; 265 (1): 78-96
22. Garcia AM, Fadel SA, Cao S, et al. T cell immunity in neonates. Immunol Res 2000; 22 (2-3): 177-90 (Pubitemid 32382232)
23. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25 (16): 3066-9 (Pubitemid 46482735)
24. Dougan G, Hormaeche C. How bacteria and their products provide clues to vaccine and adjuvant development. Vaccine 2006; 24 Suppl. 2: S2-9
25. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124 (4): 849-63 (Pubitemid 43261457)
26. Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 2004; 18 (2): 79-93 (Pubitemid 38507891)
27. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74-108
28. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl. 10: K1-16
29. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183 (1): 8-15 (Pubitemid 32043036)
30. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337 (1): 76-84 (Pubitemid 40725441)
31. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324 (1): 17-27 (Pubitemid 38737395)
32. Muñ oz N, Bosch FX, de SS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 Feb 6; 348 (6): 518-27 (Pubitemid 36159887)
33. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 Suppl. 3: S11-25 (Pubitemid 44404053)
34. Muñ oz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111 (2): 278-85 (Pubitemid 38924707)
35. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 Suppl. 1: S7-15 (Pubitemid 40332584)
36. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89 (2): 213-28 (Pubitemid 35351540)
37. Passmore J-AS, Milner M, Denny L, et al. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus- associated cervical intraepithelial neoplasia. Immunology 2006; 119 (4): 507-14 (Pubitemid 44722213)
38. Ho GY, Studentsov YY, Bierman R, et al. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13 (1): 110-6 (Pubitemid 38116628)
39. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A . *0201-restricted E7-encoded epitope. Cancer Res 1996; 56 (3): 582-8
40. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010 Nov 1; 70 (21): 8569-77
41. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89 (24): 12180-4 (Pubitemid 23004809)
42. Christensen ND, Dillner J, Eklund C, et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223 (1): 174-84 (Pubitemid 26302057)
43. Deschuyteneer M, Elouahabi A, Plainchamp D, et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™ the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010; 6 (5): 1-13
44. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69 (6): 3959-63
45. Christensen ND, Reed CA, Cladel NM, et al. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70 (2): 960-5 (Pubitemid 26029013)
46. Suzich JA, Ghim S-J, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92 (25): 11553-7 (Pubitemid 26014152)
47. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110 (3 Suppl. 1): S1-10
48. Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004; 23 (3): 316-20 (Pubitemid 39463048)
49. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8 (2): 235-47 (Pubitemid 351233716)
50. Kong NCT, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68 (5): 2298-303 (Pubitemid 43117807)
51. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982; 257 (19): 11808-15 (Pubitemid 13218648)
52. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316 (5831): 1628-32 (Pubitemid 46982038)
53. Tapping RI, Akashi S, Miyake K, et al. Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides. J Immunol 2000; 165 (10): 5780-7
54. Yang R, Murillo FM, Delannoy MJ, et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005 Jun 15; 174 (12): 7912-9 (Pubitemid 40806301)
55. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733
56. Ganley-Leal LM, Liang Y, Jagannathan-Bogdan M, et al. Differential regulation of TLR4 expression in human B cells and monocytes. Mol Immunol 2010 Nov; 48 (1-3): 82-8
57. Bernasconi NL, Onai N, Lanzavecchia A. A role for toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003 Jun 1; 101 (11): 4500-4 (Pubitemid 36857820)
58. Bourke E, Bosisio D, Golay J, et al. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003; 102 (3): 956-63 (Pubitemid 36917790)
59. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36 (4): 810-6
60. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010 Aug 31; 28 (38): 6247-55
61. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 Nov 13; 364 (9447): 1757-65 (Pubitemid 39488060)
62. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 Apr 15; 367 (9518): 1247-55
63. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 Jun 30; 369 (9580): 2161-70 (Pubitemid 46977438)
64. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009 Jul 25; 374 (9686): 301-14
65. Schwarz T, Rivera M, Valencia A, et al. Long-term safety and immunogenicity of a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in girls aged 10-14 years: 36-month follow-up [abstract]. Pediatr Infect Dis J 2009; 28 (6): e197
66. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27 (4): 581-7
67. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix™and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5 (10): 705-19
68. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5 (5): 332-40
69. Siegrist CA. Autoimmune diseases after adolescent or adult immunization: what should we expect? CMAJ 2007; 177 (11): 1352-4
70. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26 (51): 6630-8